SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 In Provectus Biopharmaceuticals, Inc. To Conta...
June 06 2014 - 3:10PM
Business Wire
The securities litigation law firm of Brower Piven, A
Professional Corporation, announces that a class action lawsuit has
been commenced in the United States District Court for the Middle
District of Tennessee on behalf of purchasers of Provectus
Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (NYSE MKT:
PVCT) publicly traded securities during the period between December
17, 2013 and May 22, 2014, inclusive (the “Class Period”), and
informs investors who wish to become proactively involved in the
litigation that they have until July 28, 2014 to seek appointment
as lead plaintiff.
If you have suffered a loss from investment in Provectus
securities purchased on or after December 17, 2013 and held through
the revelation of negative information during and/or at the end of
the Class Period, as described below, and would like to learn more
about this lawsuit and your ability to participate as a lead
plaintiff, without cost or obligation to you, please visit our
website at http://www.browerpiven.com/currentsecuritiescases.html.
You may also request more information by contacting Brower Piven
either by email at hoffman@browerpiven.com or by telephone at (410)
415-6616.
No class has yet been certified in the above action. Members of
the Class will be represented by the lead plaintiff and counsel
chosen by the lead plaintiff. If you wish to choose counsel to
represent you and the Class, you must apply to be appointed lead
plaintiff no later than July 28, 2014 and be selected by the Court.
The lead plaintiff will direct the litigation and participate in
important decisions including whether to accept a settlement and
how much of a settlement to accept for the Class in the action. The
lead plaintiff will be selected from among applicants claiming the
largest loss from investment in Company units during the Class
Period.
The complaint accuses the defendants of violations of the
Securities Exchange Act of 1934 by virtue of the defendants’
failure to disclose during the Class Period the true prospects for
PV-10 and that new skin cancer drugs being developed may have
rendered PV-10 obsolete.
According to the complaint, following an article published on
TheStreet.com on January 23, 2014 suggesting that PV-10 may be
obsolete and another article appearing on SeekingAlpha.com on May
21, 2014 asserting that the Company was tied to a stock promotion
company whose other stock recommendations had recently had trading
in their stock halted by the SEC, the shares of Provectus declined
significantly in value and then stopped trading.
Attorneys at Brower Piven have extensive experience in
litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s. If you
choose to retain counsel, you may retain Brower Piven without
financial obligation or cost to you, or you may retain other
counsel of your choice. You need take no action at this time to be
a member of the class.
Brower Piven, A Professional CorporationCharles J. Piven,
410-415-66161925 Old Valley RoadStevenson, Maryland
21153hoffman@browerpiven.com
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024